No Data
No Data
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Palatin Technologies Price Target Maintained With a $17.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Palatin Technologies (PTN)
Palatin Spikes as FDA Clears Mid-stage Trial for Weight Loss Therapy
Express News | HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 733.33% HC Wainwright & Co. → $17 Reiterates Buy → Buy 02/28/2024 733.33% HC Wainwright & Co. $
Buy Rating Endorsed for Palatin Technologies Amidst Promising Obesity Treatment Advancements